Daratumumab
Showing 226 - 250 of 273
Multiple Myeloma Stage I Trial in Salvador (Cyclo Thal Dex Daratumumab)
Unknown status
- Multiple Myeloma Stage I
- Cyclo Thal Dex Daratumumab
-
Salvador, Bahia, BrazilCEHON - Centro de Hematologia e Oncologia da Bahia
Jan 2, 2019
Infusion Reaction, Monoclonal Antibody Trial in Clovis (Montelukast 10 Mg Oral Tablet)
Recruiting
- Infusion Reaction
- Monoclonal Antibody
- Montelukast 10 Mg Oral Tablet
-
Clovis, CaliforniaCommunity Cancer Institute
Nov 8, 2021
Relapsed and/or Refractory Multiple Myeloma, Relapsed and/or Refractory Non Hodgkin Lymphoma Trial in United States (MT-0169)
Recruiting
- Relapsed and/or Refractory Multiple Myeloma
- Relapsed and/or Refractory Non Hodgkin Lymphoma
-
Los Angeles, California
- +6 more
Feb 28, 2022
Multiple Myeloma Trial (Melphalan and Treosulfan, Melphalan)
Not yet recruiting
- Multiple Myeloma
- Melphalan and Treosulfan
- Melphalan
- (no location specified)
Dec 5, 2022
Multiple Myeloma Trial in Warszawa, Poznan (Daratumumab 20 MG/ML [Darzalex])
Recruiting
- Multiple Myeloma
- Daratumumab 20 MG/ML [Darzalex]
-
Warszawa, Mazowieckie, Poland
- +1 more
Jan 2, 2019
Multiple Myeloma Trial in Athens (Daratumumab, Ixazomib, Dexamethasone)
Unknown status
- Multiple Myeloma
- Daratumumab, Ixazomib, Dexamethasone
-
Athens, Attica, GreeceGeneral Hospital of Athens "Alexandra"
Nov 20, 2018
Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)
Recruiting
- Plasma Cell Myeloma
- Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 27, 2022
Light Chain (AL) Amyloidosis Trial in Worldwide (Birtamimab, Placebo, Standard of Care Chemotherapy)
Recruiting
- Light Chain (AL) Amyloidosis
- Birtamimab
- +2 more
-
Hartford, Connecticut
- +120 more
Aug 8, 2022
Evan Syndrome, Treatment Trial in Tianjin (Anti-CD38 antibody Injection)
Recruiting
- Evan Syndrome
- Treatment
- Anti-CD38 antibody Injection
-
Tianjin, Tianjin, ChinaChinese Academy of Medical Science and Blood Disease Hospital
Aug 25, 2023
Newly Diagnosed Multiple Myeloma Trial in Spain (Bortezomib, Isatuximab, Iberdomide)
Not yet recruiting
- Newly Diagnosed Multiple Myeloma
- Bortezomib
- +4 more
-
Alcalá de Henares, Madrid, Spain
- +67 more
Sep 23, 2022
Immune Thrombocytopenia, Treatment Trial in Tianjin (CM313 Injection)
Not yet recruiting
- Immune Thrombocytopenia
- Treatment
- CM313 Injection
-
Tianjin, Tianjin, ChinaChinese Academy of Medical Science and Blood Disease Hospital
Jan 12, 2023
Relapsed/Refractory Multiple Myeloma Trial in France, United States (ISB 1342)
Recruiting
- Relapsed/Refractory Multiple Myeloma
- ISB 1342
-
Little Rock, Arkansas
- +21 more
May 10, 2022
Malignant Tumors Stated as Primary Lymphoid Haematopoietic Trial (Daratumumab)
Withdrawn
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
- Daratumumab
- (no location specified)
Jul 23, 2018
Refractory Plasma Cell Myeloma Trial in Jacksonville (Dexamethasone, Elotuzumab, Pomalidomide)
Suspended
- Refractory Plasma Cell Myeloma
- Dexamethasone
- +2 more
-
Jacksonville, FloridaMayo Clinic in Florida
Oct 18, 2021
AL Amyloidosis, Plasma Cell Dyscrasia Trial in Nanjing
Enrolling by invitation
- AL Amyloidosis
- Plasma Cell Dyscrasia
-
Nanjing, Jiangsu, ChinaNational Clinical Research Center of Kidney Diseases, Jinling Ho
Jan 26, 2021
Antiphospholipid Syndrome, Thrombocytopenia Trial in Tianjin (Anti-CD38 antibody Injection)
Recruiting
- Antiphospholipid Syndrome
- Thrombocytopenia
- Anti-CD38 antibody Injection
-
Tianjin, Tianjin, ChinaChinese Academy of Medical Science and Blood Disease Hospital
Aug 9, 2023
Multiple Myeloma Trial in Worldwide (Daratumumab)
Approved for marketing
- Multiple Myeloma
- Daratumumab
-
Phoenix, Arizona
- +78 more
Jan 11, 2019
Multiple Myeloma Trial (Belantamab mafodotin (GSK2857916) anti-BCMA-immunoconjugate)
Approved for marketing
- Multiple Myeloma
- Belantamab mafodotin (GSK2857916) anti-BCMA-immunoconjugate
- (no location specified)
Mar 9, 2021
Relapsed, Refractory Multiple Myeloma Trial in Milwaukee (RAPA-201 Autologous T cells)
Recruiting
- Relapsed, Refractory Multiple Myeloma
- RAPA-201 Autologous T cells
-
Milwaukee, WisconsinMedical College of Wisconsin
Dec 28, 2021